Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.06.2013 | special report | Ausgabe 2/2013

memo - Magazine of European Medical Oncology 2/2013

Recommendations of the Austrian Working Group on Lung Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer

memo - Magazine of European Medical Oncology > Ausgabe 2/2013
MD Helmut H. Popper, MD Ulrike Gruber-Moesenbacher, MD Leonhard Müllauer, MD Georg Hutarew, MD Michael Vesely, MD Mag Robert Pirker, MD Wolfgang Hilbe, MD Ferdinand Ploner, MD Ulrike Setinek, MD Wolfgang Hulla, MD Hans Maier, MD William Sterlacci, MD Klaus Kirchbacher, MD Rainer Kolb, MD Maximilian Hochmair, MD Gerald Webersinke, MD Elvira Stacher, MD Patricia Grabher, MD Tamara Hernler


The introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) for non-small cell lung cancer (NSCLC) with activating mutations of the EGFR has opened a new area of lung cancer treatment strategies and led to an enthusiastic search for additional mutations. Since then, numerous driver mutations such as EML4-ALK and ROS1 have been detected and specific treatment options have already been developed. However, molecular tests have to follow specific rules if applied in daily practice. The Austrian Working Group on Pulmonary Pathology and Oncology (AWGPPO) is presenting an updated version of their previous recommendation published in 2011. Several practical questions raised during the last 2 years will be addressed, such as reflex testing, selection of tissues, order of molecular tests, and the issue of resistance mechanisms.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 2/2013

memo - Magazine of European Medical Oncology 2/2013 Zur Ausgabe